Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.15

Puma Biotechnology

07/08/2025 21:22

Overview

Puma Q2 2025 product revenue rises to $49.2 mln, driven by NERLYNX demand

Adjusted EPS for Q2 beats analyst expectations, per LSEG data

Co reports net income of $5.9 mln for Q2, reversing prior year loss

Outlook

Puma expects Q3 net product revenue between $46 mln and $48 mln

Company forecasts full-year total revenue of $212–$222 mln

Puma anticipates Q3 net income between $2 mln and $4 mln

Company sees full-year net income of $23–$28 mln

Result Drivers

NERLYNX SALES - Increased demand for NERLYNX drove product revenue to $49.2 mln in Q2 2025

EXPENSE REDUCTION - Lower SG&A expenses due to decreased legal fees contributed to profitability

ALISERTIB DEVELOPMENT - Increased R&D expenses linked to alisertib study activity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$49.20 mln
Q2 Adjusted EPS
Beat
$0.15
$0.1 (3 Analysts)
Q2 EPS
$0.12
Q2 Adjusted Net Income
Beat
$7.50 mln
$4.20 mln (2 Analysts)
Q2 Net Income
$5.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Puma Biotechnology Inc is $4.00, about 18.8% above its August 6 closing price of $3.25

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nBw8yfNtda

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)